Outcomes of Terminal Complement Blockade in Adults with High-Risk Transplant-Associated Thrombotic Microangiopathy: A Comparative Analysis.

ABSTRACT: High-risk transplant-associated thrombotic microangiopathy (hrTA-TMA), marked by organ dysfunction with concurrent graft-versus-host disease (GVHD) or infection, leads to poor outcomes after allogeneic hematopoietic cell transplantation (alloHCT). Terminal complement blockade is effective in pediatric patients with hrTA-TMA, but its efficacy and safety in adult patients are unclear. To compare clinical and safety outcomes of adults with hrTA-TMA treated with terminal complement blockade versus conventional therapy. We retrospectively included adults who underwent alloHCT between 2012 and 2023 and developed hrTA-TMA, defined per Harmonization criteria. Time-to-event analyses began at TA-TMA diagnosis, with outcomes including death, relapse, and non-relapse mortality (NRM). The impact of ecu

SUBMITTER: Alhomoud M 

PROVIDER: S-EPMC12721594 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature